Mounjaro Cost Without Insurance 2026

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you searched "Mounjaro cost without insurance," you've already discovered the bad news: in April 2026, a 28-day supply of Mounjaro lists at roughly $1,112 and lands somewhere between about $987 and $1,100/month at major U.S. pharmacies with a SingleCare or GoodRx coupon. The widely advertised $25/month savings card is restricted to commercial-insurance holders, and Lilly Direct's $499/month self-pay path applies to Zepbound, not Mounjaro. For uninsured cash payers whose underlying goal is weight loss, that leaves a real question on the table: pay $1,000+/month for FDA-approved branded Mounjaro, switch to Zepbound at $499/month through Lilly Direct, or look at compounded tirzepatide. PlexusDx Tirzepatide Injection at $229–$309/month is a cash-pay compounded option that uses the same active ingredient as Mounjaro — tirzepatide — without the membership fees, retail markup, or insurance gatekeeping. This guide walks the actual Mounjaro cash-pay numbers, explains the savings-card fine print, and shows where compounded tirzepatide sits on the price ladder.

Mounjaro cost without insurance — the verified 2026 numbers

Eli Lilly's wholesale acquisition cost (WAC) for Mounjaro is $1,112.16 per 28-day supply as of January 1, 2026, up from $1,069.08 the year prior. One "fill" equals four single-dose pens — a month of once-weekly injections — and the price is identical regardless of dose strength (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Verified cash-pay prices with a SingleCare or GoodRx coupon in April 2026 range from about $987 at Harris Teeter to roughly $1,042–$1,068 at Walgreens, CVS, and Costco, with GoodRx starting prices around $1,089. None of these numbers reflect insurance — they're what you actually pay at the pharmacy counter as a cash patient with a coupon. The price is high because Mounjaro is a first-in-class dual GIP/GLP-1 receptor agonist under patent protection through 2036, with no FDA-approved generic or biosimilar tirzepatide on the U.S. market. If a Mounjaro-strength dual agonist is what you need, but $12,000+/year is not what you can spend, your three real options are: switch to Zepbound (same molecule, different brand) via Lilly Direct, work the savings-card system if you have commercial insurance, or consider compounded tirzepatide through a cash-pay protocol like PlexusDx Tirzepatide Injection.

Why the $25 Mounjaro Savings Card won't work if you're uninsured

The $25 figure is real, but it's narrower than the marketing implies. The Mounjaro Savings Card has two tiers, and both require commercial (private) prescription drug insurance. Tier 1 — if your commercial plan covers Mounjaro on its formulary — brings cost as low as $25 per fill, capped at $1,950 in annual savings across up to 13 fills per calendar year. Tier 2 — if your commercial plan does not cover Mounjaro — brings cost as low as $499 per fill with an $8,411 annual cap. Both tiers explicitly exclude uninsured patients, Medicare beneficiaries, Medicaid beneficiaries, TRICARE, and VA patients under federal anti-kickback rules. The current program runs through December 31, 2026, and Lilly can modify terms at any time. If you're uninsured, the savings card cannot be your path. If you're on government insurance, your access depends on whether your plan covers Mounjaro for type 2 diabetes — the only FDA-approved indication. For weight loss, Mounjaro is off-label, and most insurers will not cover it for that purpose regardless of plan type.

Lilly Direct — $499 is for Zepbound, not Mounjaro

Lilly Direct is Eli Lilly's direct-to-consumer cash-pay channel. As of April 2026, it sells Zepbound (tirzepatide for weight loss) at roughly $299–$499/month for self-pay vials — not the autoinjector pens. Mounjaro is not currently listed on Lilly Direct's medicines page. Lilly announced in November 2025 that Mounjaro would be added to Lilly Direct at 50–60% off list, but the rollout has not landed for retail patients in early 2026. The practical implication: if your goal is weight loss and you're paying cash, Zepbound through Lilly Direct is dramatically cheaper than Mounjaro through any retail channel, and contains the identical active ingredient (tirzepatide) at the identical doses from the same manufacturer. If your goal is type 2 diabetes management and you specifically need Mounjaro's FDA-approved diabetes label for clinical or insurance reasons, you'll likely be paying $987–$1,112/month at retail until Lilly Direct expands to Mounjaro. Either way, the $499 Lilly Direct number circulating online is a Zepbound price, not a Mounjaro price.

Compounded tirzepatide as the cash-pay alternative — how PlexusDx prices stack up

Compounded tirzepatide is a third path that exists outside both the retail-pharmacy and Lilly Direct channels. Compounded medications are prepared by licensed U.S. compounding pharmacies under federal and state compounding regulations — they are not FDA-approved finished drug products like Mounjaro or Zepbound, but they contain the same active ingredient (tirzepatide) prepared to a clinician-specified formulation. PlexusDx Tirzepatide Injection is priced at $229–$309/month across six dose levels (2.5 mg to 15 mg weekly), all-inclusive of the async provider consultation, the compounded medication, and shipping — cash-pay, no membership fee. That's $2,748–$3,708/year compared to $11,844–$13,344/year for retail Mounjaro or roughly $5,988/year for Zepbound at the upper Lilly Direct tier. PlexusDx also offers Tirzepatide Oral at $229–$509/month for patients who prefer a daily tablet over a weekly injection, GLP-Squared at $179–$325/month as a Semaglutide + Tirzepatide dual-compound stack, and the entry-tier Microdose GLP-1 Protocol at $129/month flat for patients who want the most cost-conservative GLP-1 starting point. None of these compounded options are FDA-approved finished drugs, and the regulatory framework is different from branded Mounjaro — that distinction matters and is covered in the safety section below.

Mounjaro vs Zepbound vs compounded tirzepatide — cost comparison

Here's what the annualized math looks like in April 2026 for an uninsured cash payer. Retail Mounjaro at $987–$1,112/month works out to roughly $11,844–$13,344/year. Zepbound through Lilly Direct at $299–$499/month works out to roughly $3,588–$5,988/year. PlexusDx Tirzepatide Injection at $229–$309/month works out to $2,748–$3,708/year, all-inclusive of consult, medication, and shipping. The PlexusDx compounded route is roughly 70–75% cheaper than retail Mounjaro and competitive with the lower end of Lilly Direct Zepbound. Two important caveats: (1) Zepbound is FDA-approved for weight loss in adults with obesity and obstructive sleep apnea, and is the same molecule, dose for dose, as Mounjaro; (2) compounded tirzepatide is not FDA-approved as a finished drug product, and the FDA's late-2024 determination that tirzepatide is no longer in shortage means the regulatory landscape for compounded versions has tightened. Patients evaluating cost should weigh these factors alongside the price differential rather than treating cost as the only variable.

Safety, oversight, and the boxed warning that applies to both

Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors based on rodent studies — this warning applies to FDA-approved Mounjaro and Zepbound and is part of the same safety conversation for any compounded tirzepatide product. The class side-effect profile (nausea, vomiting, diarrhea, constipation, abdominal pain, headache, plus less common pancreatitis, gallbladder disease, and acute kidney injury) is well-characterized for the active ingredient. The clinical-oversight question differs by source. Branded Mounjaro and Zepbound carry the FDA-approved label and post-market surveillance system. Compounded tirzepatide is dispensed under U.S. compounding regulations and overseen by the prescribing clinician and licensed compounding pharmacy. PlexusDx Weight Management Protocols pair compounded tirzepatide with an async clinical intake (or scheduled live consult in five states that require it) and offer the optional Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month) to baseline GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants before titration — a step neither retail Mounjaro nor Lilly Direct Zepbound includes.

Why genetics matter when you're choosing a tirzepatide path

GLP-1 and dual GIP/GLP-1 response varies meaningfully across patients. Variants in GLP1R, GIPR (the GIP receptor that gives tirzepatide its dual action), FTO, MC4R, and TCF7L2 are associated with measurably different response patterns — some patients lose weight faster than the trial averages, some plateau early, some tolerate higher doses, and some don't. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways, including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response. The result is delivered through the Peptide Pathways Report in the PlexusDx Results Portal and informs the prescribing clinician's titration approach — whether a faster-than-typical schedule, a slower one, or a tirzepatide-first vs semaglutide-first approach is more likely to fit your biology. If you're paying cash for tirzepatide either way, anchoring that spend to a measurable genetic baseline rather than population averages is a one-time $99 add-on that pays for itself if it prevents one wasted titration cycle.

Which path fits — a four-question decision frame

Question 1: Do you have commercial insurance that covers Mounjaro on its formulary? If yes, the Mounjaro Savings Card Tier 1 path at as low as $25/fill is your cheapest legitimate route. Question 2: Are you uninsured or on government insurance and your goal is weight loss? Look at Zepbound via Lilly Direct ($299–$499/month) or PlexusDx Tirzepatide Injection ($229–$309/month) before paying $987–$1,112/month for retail Mounjaro. Question 3: Do you specifically need Mounjaro's FDA-approved diabetes label and you're paying cash? Use SingleCare or GoodRx at a pharmacy like Harris Teeter, Walgreens, CVS, or Costco — expect $987–$1,100/month. Question 4: Do you want a genetic baseline informing dose and titration before you start any tirzepatide protocol? PlexusDx is the cash-pay path that includes the Precision Peptide Genetic Test as a $99 add-on to any protocol. Most uninsured weight-loss patients land on Question 2 and choose between Zepbound through Lilly Direct or compounded tirzepatide through PlexusDx based on whether they prioritize the FDA-approved finished product or the lower monthly cost.

Frequently asked questions

How much does Mounjaro cost per month without insurance?

Mounjaro's list price is $1,112.16 per 28-day supply as of January 2026. Verified cash-pay prices at major U.S. pharmacies with a SingleCare or GoodRx coupon range from about $987 (Harris Teeter) to roughly $1,100 (CVS, Walgreens, Costco) in April 2026. The price is identical regardless of dose strength.

Can I get Mounjaro for $25 without insurance?

No. The Mounjaro Savings Card is restricted to patients with commercial (private) prescription drug insurance. Uninsured patients, Medicare, Medicaid, TRICARE, and VA beneficiaries are excluded. The card has two tiers: as low as $25/fill if your commercial plan covers Mounjaro, or as low as $499/fill if your plan does not.

Is Lilly Direct $499 a Mounjaro price or a Zepbound price?

It's a Zepbound price. Lilly Direct sells Zepbound (tirzepatide for weight loss) at roughly $299–$499/month for self-pay vials. Mounjaro is not currently listed on Lilly Direct as of April 2026. Lilly announced a 2025 plan to add Mounjaro at 50–60% off list, but that rollout has not reached retail patients yet.

How does compounded tirzepatide compare on price to Mounjaro?

PlexusDx Tirzepatide Injection is priced at $229–$309/month all-inclusive of provider consult, compounded medication, and shipping. That's roughly 70–75% less than retail Mounjaro at $987–$1,112/month. Compounded tirzepatide is not an FDA-approved finished drug product, which is the regulatory tradeoff against branded Mounjaro or Zepbound.

Is compounded tirzepatide the same as Mounjaro?

The active ingredient is the same molecule — tirzepatide, a dual GIP/GLP-1 receptor agonist. The finished products differ. Mounjaro is an FDA-approved branded drug from Eli Lilly. Compounded tirzepatide is prepared by a licensed U.S. compounding pharmacy under compounding regulations and is not an FDA-approved finished drug. Both carry the boxed warning for thyroid C-cell tumor risk based on rodent studies.

What is the cheapest legitimate way to get tirzepatide without insurance?

For exact-brand Mounjaro: a local pharmacy with a SingleCare or GoodRx coupon at $987–$1,100/month. For exact-brand Zepbound (same active ingredient, FDA-approved for weight loss): Lilly Direct at $299–$499/month. For compounded tirzepatide: PlexusDx Tirzepatide Injection at $229–$309/month. Choose based on whether you need the branded FDA-approved label or are optimizing for cash-pay cost.

Does PlexusDx accept insurance for its tirzepatide protocol?

No. PlexusDx is a cash-pay platform with no membership fee. The Tirzepatide Injection Protocol is $229–$309/month all-inclusive of async provider consultation, compounded tirzepatide, and shipping. Five states require a scheduled live consult instead of async intake. PlexusDx does not bill insurance, and it does not guarantee weight-loss results.

Mounjaro Cost Without Insurance (2026): Retail Prices, Lilly Direct Reality, and the PlexusDx Cash-Pay Alternative | PlexusDx